Hennion & Walsh Asset Management Inc. Cuts Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hennion & Walsh Asset Management Inc. cut its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 7.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 184,126 shares of the company's stock after selling 15,399 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.25% of Kiniksa Pharmaceuticals worth $4,089,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth about $61,000. KLP Kapitalforvaltning AS purchased a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth about $158,000. Bellevue Group AG bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter worth about $160,000. Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after purchasing an additional 4,575 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after buying an additional 1,004 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Stock Up 2.2%

NASDAQ:KNSA traded up $0.64 during mid-day trading on Thursday, reaching $29.52. The company's stock had a trading volume of 1,058,697 shares, compared to its average volume of 499,914. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $29.75. The stock has a fifty day moving average of $23.96 and a 200-day moving average of $21.78. The firm has a market capitalization of $2.15 billion, a PE ratio of -210.84 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue was up 72.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.25) EPS. On average, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals news, insider Ross Moat sold 18,259 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the sale, the insider now owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00. Following the transaction, the chief operating officer now directly owns 77,363 shares of the company's stock, valued at approximately $1,584,394.24. This trade represents a 13.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 391,014 shares of company stock worth $10,101,143 over the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KNSA. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Finally, Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.